Background: Chronic mucocutaneous candidiasis (CMC) treatment often induces drug resistance, posing long-term challenges. A novel broad-spectrum fungal CYP51 inhibitor, VT-1598, specifically targets fungal CYP51, but not human CYP enzymes. Objectives: To determine the efficacy of VT-1598 in the treatment of oral Candida infection caused by fluconazole-susceptible and -resistant clinical isolates. Methods: The MICs of VT-1598 and fluconazole for 28 Candida isolates recovered from patients with inherited CMC were determined using CLSI M27-A3 and M27-S4 guidelines. Plasma and tongue VT-1598 or fluconazole concentrations were measured in mice following oral administration to determine tissue distribution. Tongue fungal load was determined in IL-17 signalling-deficient Act1-/- mice following sublingual Candida albicans infection and oral treatment with fluconazole or VT-1598. Results: Among the 28 Candida isolates, 10 (36%) had fluconazole MICs of ≥4 mg/L, whereas VT-1598 demonstrated potent in vitro activity against all isolates (MIC90, 0.125 mg/L). After oral administration, VT-1598 levels in mouse plasma and tongue were significantly greater than those of fluconazole. In vivo, VT-1598 exhibited significant efficacy against fluconazole-susceptible and -resistant C. albicans, even at low drug doses. Furthermore, after a 10 day washout period, tongue fungal burdens in fluconazole-treated mice returned to vehicle control levels, whereas, in contrast, they were undetectable in mice treated with VT-1598. Conclusions: VT-1598 effectively controls in vitro growth of mucosally derived Candida clinical isolates, including fluconazole-resistant strains. In vivo, VT-1598 eliminates C. albicans, even after a long washout period or at low doses. Therefore, VT-1598 is a promising drug candidate that may significantly improve treatment options for CMC patients.
Background: Chronic mucocutaneous candidiasis (CMC) treatment often induces drug resistance, posing long-term challenges. A novel broad-spectrum fungal CYP51 inhibitor, VT-1598, specifically targets fungal CYP51, but not human CYP enzymes. Objectives: To determine the efficacy of VT-1598 in the treatment of oral Candida infection caused by fluconazole-susceptible and -resistant clinical isolates. Methods: The MICs of VT-1598 and fluconazole for 28 Candida isolates recovered from patients with inherited CMC were determined using CLSI M27-A3 and M27-S4 guidelines. Plasma and tongue VT-1598 or fluconazole concentrations were measured in mice following oral administration to determine tissue distribution. Tongue fungal load was determined in IL-17 signalling-deficient Act1-/- mice following sublingual Candida albicans infection and oral treatment with fluconazole or VT-1598. Results: Among the 28 Candida isolates, 10 (36%) had fluconazole MICs of ≥4 mg/L, whereas VT-1598 demonstrated potent in vitro activity against all isolates (MIC90, 0.125 mg/L). After oral administration, VT-1598 levels in mouse plasma and tongue were significantly greater than those of fluconazole. In vivo, VT-1598 exhibited significant efficacy against fluconazole-susceptible and -resistant C. albicans, even at low drug doses. Furthermore, after a 10 day washout period, tongue fungal burdens in fluconazole-treated mice returned to vehicle control levels, whereas, in contrast, they were undetectable in mice treated with VT-1598. Conclusions: VT-1598 effectively controls in vitro growth of mucosally derived Candida clinical isolates, including fluconazole-resistant strains. In vivo, VT-1598 eliminates C. albicans, even after a long washout period or at low doses. Therefore, VT-1598 is a promising drug candidate that may significantly improve treatment options for CMCpatients.
Authors: Christopher M Yates; Edward P Garvey; Sammy R Shaver; Robert J Schotzinger; William J Hoekstra Journal: Bioorg Med Chem Lett Date: 2017-06-15 Impact factor: 2.823
Authors: William J Hoekstra; Edward P Garvey; William R Moore; Stephen W Rafferty; Christopher M Yates; Robert J Schotzinger Journal: Bioorg Med Chem Lett Date: 2014-06-09 Impact factor: 2.823
Authors: Elise M N Ferre; Stacey R Rose; Sergio D Rosenzweig; Peter D Burbelo; Kimberly R Romito; Julie E Niemela; Lindsey B Rosen; Timothy J Break; Wenjuan Gu; Sally Hunsberger; Sarah K Browne; Amy P Hsu; Shakuntala Rampertaap; Muthulekha Swamydas; Amanda L Collar; Heidi H Kong; Chyi-Chia Richard Lee; David Chascsa; Thomas Simcox; Angela Pham; Anamaria Bondici; Mukil Natarajan; Joseph Monsale; David E Kleiner; Martha Quezado; Ilias Alevizos; Niki M Moutsopoulos; Lynne Yockey; Cathleen Frein; Ariane Soldatos; Katherine R Calvo; Jennifer Adjemian; Morgan N Similuk; David M Lang; Kelly D Stone; Gulbu Uzel; Jeffrey B Kopp; Rachel J Bishop; Steven M Holland; Kenneth N Olivier; Thomas A Fleisher; Theo Heller; Karen K Winer; Michail S Lionakis Journal: JCI Insight Date: 2016-08-18
Authors: Nathan P Wiederhold; Hoja P Patterson; Bich Hue Tran; Christopher M Yates; Robert J Schotzinger; Edward P Garvey Journal: J Antimicrob Chemother Date: 2018-02-01 Impact factor: 5.790
Authors: Timothy J Break; Jigar V Desai; Mukil Natarajan; Elise M N Ferre; Christina Henderson; Adrian M Zelazny; Ulrich Siebenlist; William J Hoekstra; Robert J Schotzinger; Edward P Garvey; Michail S Lionakis Journal: J Antimicrob Chemother Date: 2018-01-01 Impact factor: 5.790
Authors: Lisa F Shubitz; Hien T Trinh; John N Galgiani; Maria L Lewis; Annette W Fothergill; Nathan P Wiederhold; Bridget M Barker; Eric R G Lewis; Adina L Doyle; William J Hoekstra; Robert J Schotzinger; Edward P Garvey Journal: Antimicrob Agents Chemother Date: 2015-09-14 Impact factor: 5.191
Authors: Andrew T Nishimoto; Nathan P Wiederhold; Stephanie A Flowers; Qing Zhang; Steven L Kelly; Joachim Morschhäuser; Christopher M Yates; William J Hoekstra; Robert J Schotzinger; Edward P Garvey; P David Rogers Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Jigar V Desai; Amanda Urban; Michail S Lionakis; Alexandra F Freeman; Doris Z Swaim; Benjamin Colton; Lilian W Kibathi; Elise M N Ferrè; Pamela Stratton; Melissa A Merideth; Sally Hunsberger; Theresa Matkovits; Raphael Mannino; Steven M Holland; Edmund Tramont Journal: Antimicrob Agents Chemother Date: 2022-06-14 Impact factor: 5.938
Authors: Andrew T Nishimoto; Sarah G Whaley; Nathan P Wiederhold; Qing Zhang; Christopher M Yates; William J Hoekstra; Robert J Schotzinger; Edward P Garvey; P David Rogers Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Timothy J Break; Vasileios Oikonomou; Nicolas Dutzan; Jigar V Desai; Marc Swidergall; Tilo Freiwald; Daniel Chauss; Oliver J Harrison; Julie Alejo; Drake W Williams; Stefania Pittaluga; Chyi-Chia R Lee; Nicolas Bouladoux; Muthulekha Swamydas; Kevin W Hoffman; Teresa Greenwell-Wild; Vincent M Bruno; Lindsey B Rosen; Wint Lwin; Andy Renteria; Sergio M Pontejo; John P Shannon; Ian A Myles; Peter Olbrich; Elise M N Ferré; Monica Schmitt; Daniel Martin; Daniel L Barber; Norma V Solis; Luigi D Notarangelo; David V Serreze; Mitsuru Matsumoto; Heather D Hickman; Philip M Murphy; Mark S Anderson; Jean K Lim; Steven M Holland; Scott G Filler; Behdad Afzali; Yasmine Belkaid; Niki M Moutsopoulos; Michail S Lionakis Journal: Science Date: 2021-01-15 Impact factor: 47.728